Tanizaki Yuka, Fukutomi Motoki, Onishi Takayuki, Ando Tomo, Takanashi Shuichiro, Tobaru Tetsuya
Department of Cardiology, Kawasaki Saiwai Hospital, Kawasaki, Kanagawa, Japan.
Department of Cardiac Surgery, Kawasaki Saiwai Hospital, Kawasaki, Japan.
Heart Vessels. 2025 Feb 5. doi: 10.1007/s00380-025-02514-w.
Access site bleeding is a complication which may occur during Impella support (Abiomed, Danvers, MA, USA), possibly due to unstable fixation of the device in the groin. Using a large-bore sheath for Impella insertion may reduce this complication. However, the efficacy and safety of this strategy are still unknown. The main aim of this study was to assess whether employing a large-bore sheath during Impella insertion mitigates access site bleeding without increasing limb ischemia. All consecutive patients who received either the Impella 2.5 or CP for cardiogenic shock from September 2019 to February 2023 were included in this study. We compared patients who underwent Impella insertion using the conventional peel-away introducer and the attached sheath (repositioning sheath) and patients in whom the Impella was inserted using a 16 Fr sheath. All patients received antegrade perfusion with a 4Fr sheath to prevent limb ischemia at the Impella site. The primary outcome was access site major bleeding: 36 patients were treated with a 16 Fr sheath and 39 were treated with a conventional sheath. The use of a 16 Fr sheath was associated with a significant reduction in major bleeding (33.0% vs. 64.0%, p = 0.01) in comparison to the conventional sheath. After adjusting for covariates, the risk of major bleeding at the access site in the 16 Fr sheath group was significantly lower than that in the conventional sheath group (adjusted odds ratio, 0.294; 95% confidence interval 0.087-0.991; p = 0.048). The insertion of Impella through a 16 Fr sheath significantly reduced the risk of major bleeding at the access site in comparison to the conventional sheath.
穿刺部位出血是在使用Impella(美国马萨诸塞州丹弗斯市的Abiomed公司生产)进行支持治疗期间可能发生的一种并发症,可能是由于该装置在腹股沟处固定不稳定所致。使用大口径鞘管进行Impella植入可能会减少这种并发症。然而,该策略的有效性和安全性仍不明确。本研究的主要目的是评估在Impella植入过程中使用大口径鞘管是否能减轻穿刺部位出血,同时不增加肢体缺血的风险。本研究纳入了2019年9月至2023年2月期间所有连续接受Impella 2.5或CP治疗心源性休克的患者。我们比较了使用传统可剥离导入器及附属鞘管(重新定位鞘管)进行Impella植入的患者和使用16 Fr鞘管进行Impella植入的患者。所有患者均通过4Fr鞘管进行顺行灌注,以预防Impella部位的肢体缺血。主要结局是穿刺部位大出血:36例患者使用16 Fr鞘管治疗,39例患者使用传统鞘管治疗。与传统鞘管相比,使用16 Fr鞘管与大出血显著减少相关(33.0%对64.0%,p = 0.01)。在对协变量进行调整后,16 Fr鞘管组穿刺部位大出血的风险显著低于传统鞘管组(调整后的优势比为0.294;95%置信区间为0.087 - 0.991;p = 0.048)。与传统鞘管相比,通过16 Fr鞘管植入Impella显著降低了穿刺部位大出血的风险。